Introduction
Glaucoma is the leading cause of irreversible blindness worldwide [1] with primary open angle glaucoma (POAG) being the most prevalent subtype. However primary angle-closure glaucoma (PACG) is responsible for almost half of all glaucoma blindness. [2] Family history and ethnicity are important risk factors for PACG. The disease is more prevalent amongst Asians and Eskimos than in Caucasians and Africans. [3] In addition, first degree relatives of patients with PACG have a higher probability of developing narrow angles. [4, 5] The number of patients with PACG worldwide is expected to rise from around 16 million in 2010 to 21 million by the year 2020 [6] with the majority of bilaterally blind PACG patients expected to be of Asian ethnicity. [7] Patients with PACG share certain anatomical biometric features including short anterior chamber depth with narrowing in the irido-corneal drainage angle, increased lens thickness and anterior apposition of the lens, short axial length and hyperopic (farsightedness) refractive error. [8] The leading cause of PACG is from obstruction of the trabecular meshwork, which leads to the accumulation of aqueous humor and subsequent increase in intraocular pressure. This in turn causes progressive destruction of the optic nerve with corresponding loss of the peripheral visual field. [6] PACG is a complex heterogeneous disease. Recently Vithana and colleagues conducted a large two-staged genome-wide association study and reported three susceptibility loci: rs11024102 in PLEKHA7; rs3753841 in COL11A1, and rs1015213 located between PCMTD1 and ST18. [9] Prior to this, evaluation of PACG genetics Archived at the Flinders Academic Commons: http://dspace.flinders.edu.au/dspace/ has been conducted through evaluation of candidate genes chosen for biological plausibility or association with similar phenotypes. Several genes have previously been reported to be associated with other subtypes of glaucoma. For example Cytochrome P450 (CYP1B1) is well known to cause primary congenital glaucoma (PCG), [10, 11] while Endothelial nitric oxidase synthase (eNOS) [12, 13] and Neurotrophin-4 (NTF4) have been implicated in primary open angle glaucoma (POAG). [14] As all three types of glaucoma (POAG, PCG and PACG) are characterised by destruction of the optic nerve and progressive increase in the cup:disc ratio, generally with elevated intraocular pressure, we hypothesised that variations within these POAG and PCG genes may also be associated with PACG.
CYP1B1 is the most common gene known to be involved with the pathogenesis of PCG. [15, 16] It accounts for around 20% of PCG cases in Australia. [17] Sarfarazi and colleagues [10] hypothesized that CYP1B1 [OMIM 601771] is involved in the development of the anterior chamber angle of the eye, making it a gene of interest for PACG. Chakrabarti and colleagues [18] sequenced the coding region of the gene and found association of mutations with PACG in an Indian cohort consisting of 90 cases and 200 controls. A smaller study of 29 PACG patients from the Middle East did not report any known or novel polymorphisms in CYP1B1, using direct sequencing. [19] Nitric oxide (NO) is synthesized in the vascular endothelium by endothelial nitric oxide synthase 3 (also known as eNOS), from the substrate L-arginine. [20] eNOS [OMIM 163729] over expression is thought to be neuroprotective by causing vasodilation and increased blood flow in human eye tissues. [21] Overexpression of eNOS was also reported to lower intraocular pressure in the mouse eye by increasing Archived at the Flinders Academic Commons: http://dspace.flinders.edu.au/dspace/ the pressure dependent drainage. [22] Other factors such as asymmetric dimethylarginine (ADMA) and symmetric dimethylarginine (SDMA) play an inhibitory role in the production of NO. Our laboratory found that serum levels of both ADMA and SDMA are significantly elevated in patients with advanced POAG suggesting dysregulation of the NO system in this disease. [23] Furthermore NO enhances the activity of Matrix metalloprotinase-9 (MMP9) [24] which has also been reported to be associated with PACG. [25, 26] Alteration in MMP9 activity during eye development may lead to hyperopic refractive error which is a risk factor for PACG. [26, 27] It has been proposed that alteration of eNOS expression causes impairment of blood flow and subsequent development of angleclosure. The 27-bp variable number of tandem repeat (VNTR) polymorphism in intron 4 of eNOS is believed to alter the production of nitric oxide and cause vascular deregulation. [28] This variation was found to be associated with PACG in Pakistani cohorts. [29] A study of Han Chinese used tag SNPs to identify association of common variants in the eNOS gene in 88 patients with PACG, but no associations were observed. [30] Heterozygous mutations in NTF4 [OMIM 162662] were recently reported to be responsible for 1.7% of POAG cases of European descent. [14] Neurotrophin plays a vital role in the neuronal cell development, survival and differentiation and it was suggested that the pathway may also prevent neuronal damage in retinal ganglion cells. [14] Two studies have looked for association with PACG in Indian [31] and Caucasian European [32] populations respectively by sequencing the coding exons, but failed to detect association. Thus, although these three genes are plausible candidates, results are inconsistent between published studies and even less so across ethnicities. Thus, in this study, we aimed to investigate the association between tag SNPs in these three genes and PACG in both Australian and Nepalese cohorts in order to determine if common variation in these genes could contribute to disease in these populations. individuals. The Australian control cohort was ascertained from nursing home facilities in Adelaide, South Australia. Nepalese controls were participants in a population based study of Kathmandu, Nepal, in which the individuals were chosen specifically to be matched for age, gender and ethnic group to the Nepalese cases [34] . Each participant underwent a complete eye examination including; slit lamp examination of the anterior chamber, gonioscopy, best corrected visual acuity, measurement of intraocular pressure, fundus examination with special attention to optic disc parameters, and visual field assessment. Refraction was carried out using a streak retinoscope (Beta 200, Heine, Germany), which was followed by a subjective refraction [34] .
Genomic DNA was extracted from peripheral whole blood using the QiaAmp Blood Genotyping was conducted using the iPLEX Gold chemistry (Sequenom Inc, San We further analysed the association between eNOS and MMP9 with PACG in the Australian cohort by comparing the combined risk alleles with the protective one using chi-square test. The data for MMP9 was that previously published on a subset of the Australian cohort. [25] We selected the significant SNP from each gene eNOS rs3793342 and MMP9 rs17576.
The power of this study at α=0.05 was assessed using the Genetic Power Calculator.
[39] The prevalence is similar in both Australian 0.4% [40] Figure 1 .
The minor allele frequencies and allelic association p-values of typed SNPs in the
Australian cohort are presented in Table 2 . Three SNPs in eNOS were found to show (Table 3) .
When we further analysed the association between eNOS and MMP-9 with PACG in the Australian cohort, a significant difference in the rate of PACG was found between individuals carrying the risk alleles of both SNPs rs17576 in MMP-9 and rs3793342 in eNOS (105 individuals) with those who do carry the protective allele only (264 individuals) with p-value 0.048 (OR 2.8).
No statistically significant association was observed across the CYP1B1 or NTF4 loci.
The allele frequencies and association p-values of typed SNPs in the Nepalese cohort are presented in Table 4 CYP1B1 is well known for its association with primary congenital glaucoma (PCG).
[ 11, 42, 43] It is expressed in tissues of the anterior chamber of the eye such as ciliary body, iris and trabecular meshwork. [29, 30] CYP1B1 was hypothesized to take part in the normal development and function of the eye and is involved in the development of the anterior chamber angle. [10] Association was found with PACG in an Indian population [30] , but not in a Middle Eastern cohort using sequencing methodology. [19] Here we genotyped tag SNPs to look for common variations in and around the gene. Our study shows nominal association in the Nepalese cohort under both single SNP and haplotypic analyses, however this association was not considered significant given the number of tests conducted. Thus, a larger cohort will be required to confirm this putative association.
When ocular tissues are subjected to stress, nitric oxide (NO) is released from the ocular vascular endothelium causing an increase in the ocular blood flow and oxygen delivery to the retina. [44] NO is produced from the endothelial nitric oxide synthase (eNOS or NOS3) enzyme. NO synthesis sites are abundantly located in the ciliary muscle and the outflow pathway of normal human eye. It has been hypothesized to be involved in IOP regulation, either directly through affecting the outflow resistance at the level of the trabecular meshwork, or indirectly through affecting the tone of the ciliary muscle. [45] In addition to a role in IOP modulation, eNOS also affects the blood flow to the optic nerve via altering the dilation of the ocular vasculature,. [46] This could be important in determining the nerve's response to stress and dysfunction could lead to retinal ganglion cell death. eNOS was shown to be significantly associated with PACG in our Australian cohort at both the allelic and haplotypic level, suggesting that NO regulation plays a pathogenic role in PACG.
NO enhances expression of MMP9. [24] As we have previously reported an association of the MMP9 gene with PACG in this Australian cohort [25] we evaluated the data at both genes combined and show that patients carrying PACG risk alleles at both MMP9 and eNOS have double the risk of developing the disease compared to carrying no risk alleles. As the genetic architecture of PACG is unravelled, more detailed genetic risk matrices could be developed, which will better predict which patients with primary angle-closure suspect are likely to progress to PACG and thus require close monitoring.
NTF4 variants were reported to have a minor contribution in the pathogenesis of POAG. [47] Variations in NTF4 were not associated with PACG in an Indian population. [31] This study reported that the most prevalent variant, A88V, was present in controls (4.91%) at a higher frequency than in cases (2.85%) [48] which is opposite to the findings in a large cohort of POAG. [14] Neither of our cohorts showed robust association at this locus. Thus NTF4 is unlikely to be a risk locus for PACG.
In conclusion, we find no evidence for association of NTF4 or CYP1B1 with PACG in either the Australian or Nepalese cohort. SNPs and haplotypes in the eNOS gene are associated with PACG in the Australian cohort. The lack of association of this gene in the Nepalese may be due to a true negative finding, or insufficient power in this cohort to detect an effect and larger cohorts will be required to determine this.
The NO pathway has long been implicated in glaucoma. The findings here may indicate common molecular pathways leading to optic nerve susceptibility to glaucoma relevant to both POAG and PACG. (A)
